A study to assess effectiveness and safety of topical insulin on wound healing
Phase 4
- Conditions
- Health Condition 1: T07- Unspecified multiple injuries
- Registration Number
- CTRI/2024/02/063020
- Lead Sponsor
- Dr Meenu Thomas
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age18-65 years old
Either gender
Class I and II wound classifications as per CDC
Wound surface area (less than 20cm2)
Patients willing to give informed consent
Exclusion Criteria
Pregnancy
Patients on immunosuppressive treatment
Wounds that are complicated (e.g., Bleeding or infection)
Medications that may impact the study’s outcome
Cardiovascular illnesses, Peripheral artery disease or Renal and hepatic failure
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the effectiveness of topical insulin on wound healingTimepoint: Wound area in mm square shall be measured at day zero then at day 7 and then 14.
- Secondary Outcome Measures
Name Time Method To study effectiveness & safety of topical insulin on wound healingTimepoint: For effectiveness <br/ ><br>Wound depth in mm measured at day 7 & 14 <br/ ><br>The average time in which granulation tissue appears measured. <br/ ><br>For safety <br/ ><br>Random blood glucose 10 minutes before & after insulin application measured. <br/ ><br>Spontaneously reported Adverse Drug Reactions (ADRs) noted as per ADR checklist at day zero then at day 7 & 14. <br/ ><br> <br/ ><br>